Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05787496 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
A Phase 1 study, sponsored by NextCure.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05787496: Clinical Trial Phase 1 study, sponsored by NextCure.
NCT05787496 is a Phase 1 study that was terminated before completion, run by NextCure. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05787496, a Phase 1 study, was terminated before completion, sponsored by NextCure.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
Primary Outcome
Toxicity grading per NCI CTCAE v5.0.
Interventions
- DRUG NC525
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 1 |
Why NCT05787496 stopped before completion
NCT05787496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which NC525 is the first listed.
NCT05787496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05787496 about?
NCT05787496 is a clinical study titled "A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms". This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
What is the current status of trial NCT05787496?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-02-28. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT05787496?
The interventions under investigation include: NC525 (DRUG).
Who is sponsoring clinical trial NCT05787496?
This trial is sponsored by NextCure, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05787496's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI